Atibuclimab

• Target :

  TLR|||TNF

• Related Pathways :

  Immunology/Inflammation|||Apoptosis

• Purity :

  0.95

• Bioactivity :

  Atibuclimab is a chimeric monoclonal antibody targeting CD14, consisting of a mouse variable region and a human IgG4 Fc region. Atibuclimab can be used to treat amyotrophic lateral sclerosis. Atibuclimab reduces LPS-induced disease and inhibits LPS-induced pro-inflammatory cytokine release, delaying the release of anti-inflammatory cytokine soluble TNF receptor type I.

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  2417175-94-9